Patient compliance and drug failure in protease inhibitor monotherapy.
Patient compliance and drug failure in protease inhibitor monotherapy.
复制标题
蛋白酶抑制剂单一疗法的患者依从性和药物失败。
DOI：
10.1001/jama.1996.03540240033024
复制
发表时间：
1996
期刊：
影响因子：
--
通讯作者：
T. Blaschke
中科院分区：
文献类型：
--
作者：
G. Vanhove;J. Schapiro;M. Winters;T. Merigan;T. Blaschke
致《编辑》。-我们进行了一项关于沙奎那韦的2剂研究，其中40名人类免疫缺陷病毒1型(HIV-1)阳性患者每天服用3或6粒200毫克的沙奎那韦胶囊(英国韦尔文罗氏产品)，每天6次(总剂量为3600毫克/天或7200毫克/天)。1对参与研究的早期患者队列的分析表明，以HIV-1血浆RNA拷贝数衡量的应答持续时间在两组中差异很大。这种变异不是单靠耐药突变的发展来解释的。为了调查患者对这种强化疗法依从性的降低是否可以解释观察到的病毒应答的变化，我们监测了其余患者在进入高剂量组治疗的最初24周时的服药行为，方法是使用药物容器封闭或盖子，记录打开和关闭的准确日期和时间
To the Editor. —We conducted a 2-dose study of saquinavir in which 40 human immunodeficiency virus type 1 (HIV-1)positive patients received either three or six 200-mg capsules of saquinavir (Roche Products, Welwyn, United Kingdom) 6 times daily (total dose, 3600 mg/d or 7200 mg/d). 1 Analysis of an early cohort of patients enrolled in the study demonstrated that the duration of the response as measured by HIV-1 plasma RNA copy number varied widely within the 2 groups. This variation was not accounted for by the development of resistant mutations alone. To investigate whether decreased patient compliance with this intensive regimen could explain the observed variation in viral responses, we monitored drug-taking behavior in the remaining patients on their enrollment into the high-dose group for the initial 24 weeks of therapy using medication container closures or caps that record the precise date and time of the opening and closing of the